2
D. Wu et al. / Journal of Molecular Structure 1199 (2020) 126938
driving force for the employment of Cu (II) ion is its low toxicity,
which can be further reduced by formation of the coordination
complexes. In addition, Cu (II) complexes have been used as anti-
cancer agents because of their permeability selective to cancer cell
membranes, and many of these complexes are active against
platinum-resistant cancer cell lines [19,20]. Besides, recent litera-
tures have shown that some Ni(ll)-based complexes also reveal
potential anticancer activities [21e23]. In the design of metal-
organic anticancer drugs, the effects of the metal ions and the
organic ligands are two key factors which contribute to the anti-
cancer activity of the targeted anticancer drugs. To study the co-
ordination surrounding along with the metal type effects on the
anticancer activity of the resulting metal-organic complexes, in this
research, two Schiff base ligands 2-((ethylamino)methyl)-6-
methoxyphenol (HL1) and (E)-2-(((2-(dimethylamino)ethyl)
imino)methyl)-6-methoxyphenol (HL2) with bi-nucleating or tri-
nucleating mode have been successfully prepared via an one step
organic condensation reaction, which were further applied in the
synthesis of three new Ni(II) and Cu(II)-containing coordination
complexes [Cu(L1)2](EtOH) (1), [Ni(L1)2](EtOH) (2) and
[Cu(L2)(HL2)(SCN)](MeOH)2 (3) (Scheme 1). Furthermore, the green
grinding technique has been used to decrease the particle diameter
of complexes 1e3, thus forming nano-complexes. We also evalu-
ated the cell viability and proliferation of MCF7 human breast
cancer cells after treated with nanoparticles 1e3. Firstly, we eval-
uated the anticancer effect of nanoparticles 1e3 on MCF7 cells with
CCK-8 assay, results indicated only nanoparticle 1 could inhibit the
proliferation and activity of MCF7 cells, and had no cytotoxicity to
normal human cells. Further, we convinced that nanoparticle 1
could induce apoptosis and ROS accumulation in MCF7 cells by
triggering mitochondrial fragmentation. In general, these findings
mainly reflect that the compound has good anticancer activity in
the treatment of human breast cancer.
thermogravimetric analyzer was used for thermogravimetric
analysis in nitrogen atmosphere with heating rate of 10 C/min. On a
Rigaku Dmax 2500 diffractometer which has Cu-K
a radiation
(
l
¼ 1.5418 Å), we carried out the powder X-ray diffraction ana-
lyses. We determined the morphology of the nanostructured
compound (S-4200, Hitachi, Japan) via scanning electron micro-
scopy. Ultrasound was produced via a multi-wave KQ2200DE with
40 kHz frequency. Fourier transform infrared data were obtained
from KBr pellets in the range of 4000ꢀ400 cmꢀ1 on a 2000 spec-
trometer (Fig. S1). On
a PerkinElmer lambda which is 35
ultravioletevisible spectrophotometer we recorded the electronic
spectra (Fig. S2).
The normal lung cell line BEAS-2B and human breast cancer cell
line MCF7 was purchased from American Type Culture Collection
(ATCC, Rockville, MD), then cultured in ATCC-formulated RPMI-
1640 (Gibco, NY, USA) and Dulbecco's modified Eagle's medium
(DMEM; Gibco, NY, USA), respectively. 2% L-glutamine, 10% (V/V)
heat inactivated fetal bovine serum (FBS) as well as 100 U/mL
penicillin Streptomycin Solution were added to the culture me-
dium. The cells were cultured at 5% CO2, 37 ꢁC. On the basis of the
cell states, the culture medium was replaced, followed by passage
when 80% of them were fused.
2.2. Preparation of complexes 1e3
For complex 1, we added Cu(NO3)2$3H2O which is 0.24 g and
1 mmol and Schiff base ligand HL1 which is 0.181 g and 1 mmol into
ethanol solution of 20 mL and mixed them fully by magnetic stir-
ring. The mixture was cooled to room temperature after reflux for
2 h. We filtered the blue precipitation of Cu(II) complex which we
obtained, then washed it in cold ethanol of 15 mL, and dried by
anhydrous CaCl2 in vacuum. The obtained solid was then dissolved
in the acetonitrile and then kept silence for two weeks to afford the
single crystals of complex 1 suitable for X-ray diffraction. Yield:
160 mg (41%, based on Cu(NO3)2$3H2O). Anal. Calc for
1
2. Experimental
(C22H30CuN2O5): C, 56.70; H, 6.49; N, 6.01%. Found: C, 56.59; H,
6.36; N, 5.94%. UVeVis: lmax (nm) (ε, Mꢀ1, cmꢀ1) (CH3OH): 233
(6.7 ꢂ 103), 268 (3.6 ꢂ 103), 333 (2.4 ꢂ 103), 410 (1.4 ꢂ 103).
The synthesis method of complex 2 was similar to that of
complex 1 except Ni(NO3)2$6H2O which is 0.29 g and 1 mmol has
been used to replace the Cu(NO3)2$3H2O. Yield: 201 mg (53%, based
on Ni(NO3)2$3H2O). Anal. Calc for 2 (C22H30N2NiO5): C, 57.30; H,
6.56; N, 6.07%. Found: C, 56.68; H, 6.62; N, 6.01%. UVeVis: lmax
(nm) (ε, Mꢀ1, cmꢀ1) (CH3OH): 231 (1.2 ꢂ 104), 270 (6.6 ꢂ 103), 340
(2.8 ꢂ 103), 430 (1.4 ꢂ 103), 540 (9.5 ꢂ 102).
2.1. Chemicals and measurements
All chemicals were available on the market and were utilized
with no further purified. DMSO was applied as the solvent medium
in the biological studies. We prepared the two organic ligands by
utilizing the literature approach [24]. The elements of N, H and C
were analyzed by Perkinelemer 240C analyzer. PE diamond
For complex 3, we added NaSCN which is 0.08 g and 1 mmol as
well as HL2 which is 0.448 g and 2.0 mmol to CH3OH of 20 ml and
dissolved them. Then we put the required metal salt
Cu(NO3)2$3H2O which is 0.24 g and 1 mmol) to CH3OH of 20 mL.
The solution was refluxed for about 3 h. After the methanol solution
was cooled to room temperature, the blue bulk single crystal of 3
was acquired by slow evaporation. Yield: 201 mg (53%, based on
Cu(NO3)2$3H2O). Anal. Calc for C27H42CuN5O6S: C, 51.62; H, 6.74; N,
11.15%. Found: C, 51.26; H, 6.26; N, 11.23%. UVeVis: lmax (nm) (ε,
Mꢀ1
,
cmꢀ1
)
(CH3OH): 230 (1.3 ꢂ 104), 270 (6.8 ꢂ 103), 342
(2.4 ꢂ 103), 426 (1.5 ꢂ 103), 570 (1.9 ꢂ 103).
The prepared complexes 1e3 were dissolved in 1% DMSO for
further experiment.
2.3. Crystal structure and refinement
Using a Xcalibur, Eos Gemini CCD diffractometer (Agilent
Technologies Inc) equipping graphite-monochromatized Enhance
(Mo) X-ray Source (
collect the single-crystal data for compounds 1e3. The data was
l
¼ 0.71073 Å) and 4ꢀ
u scan technology to
Scheme 1. The synthesis routes for the complexes 1e3.